You are here: Home / Patient Studies / Rheumatoid Arthritis

Rheumatoid arthritis is a chronic illness marked by inflammation of the lining of the joints. The symptoms include pain, swelling and stiffness in the joints; ultimately, the disease can result in loss of function and disability. More than 2 million adults in the U.S. have rheumatoid arthritis.

 

eliza Our TeamEliza Chakravarty, M.D.
Associate Member, Arthritis & Clinical Immunology

aberle Our TeamTeresa Aberle, PA-C
Physician’s Assistant

For more information on any of the studies listed below, call (405) 271-7805 or email clinic@omrf.org.

Studies in which participants receive new (investigational) treatments:

CENTOCOR, Protocol CNTO148ART3002.  A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept (ENBREL®) or Adalimumab (HUMIRA®). (Currently Recruiting)

Abbott, Protocol M12-071(MUSICA). A Multicenter, Double-Blind, Randomized, Parallel-Arm Study to Determine the Effect of Methotrexate Dose on Clinical Outcome and Ultrasonographic Signs in Subjects with Moderately to Severely Active Rheumatoid Arthritis Treated with Adalimumab. (Currently Recruiting)

Eli Lilly and Company, Protocol H9B-MC-BCDV. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to One or More TNF-α Inhibitors. (Currently Recruiting)

Roche, Protocol NA25220. A randomized, double-blind, parallel-group study of safety and the effect on clinical outcome of tocilizumab SC versus placebo SC in combination with traditional disease modifying anti-rheumatic drugs (DMARDs) in patients with moderate to severe active rheumatoid arthritis. (Currently Recruiting)

Pfizer, Inc., Protocol A3921024. A Long-Term, Open-Label Follow-up Study of Tasocitinib (CP-690,550) for Treatment of Rheumatoid Arthritis. (Ongoing Closed Recruitment)

Eli Lilly and Company, Protocol H9B-MC-BCDP. A Phase 3b, Multicenter, Open-Label to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA). (Rollover Recruitment)